Supplemental Information EXPERIMENTAL PROCEDURES Cells and Reagents- Peripheral blood mononuclear cells (PBMCs) were acquired from consenting CLL patients at the Moores Cancer Center at the University of California San Diego (UCSD) in compliance with the Declaration of Helsinki and the institutional review board of UCSD. PBMCs were isolated from blood by Ficoll-Paque (GE Healthcare) density gradient centrifugation as previously described (16). Ramos cells were acquired from ATCC. EHEB cells were a gift from Dr. Paul Insel at UCSD and WaC3CD5+ cells were generated by Dr. John Byrd at Ohio State University. DNA and RNA Isolation- Prior to DNA and RNA isolation, CLL B cells were purified from PBMCs by negative selection using magnetic associated cell sorting (MACS) (Miltenyi Biotec) to remove CD14+ monocytes and CD2+ T cells, leading to >99% CLL cell purity. Normal B cells were purified from PBMCs of healthy donors (San Diego Blood Bank) using the MACS B cell Isolation Kit II and were determined to be >90% pure by flow cytometry analysis (CD19+/CD3/CD14- cells). Cell lysates were homogenized with QIAshredders prior to DNA and RNA isolation using the AllPrep DNA/RNA mini kit (Qiagen). Quantitative PCR- One microgram of RNA was reverse transcribed using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems). The cDNAs generated were then analyzed in triplicates using SYBR-Green PCR mix (Applied Biosystems). All values were normalized to GAPDH expression. Primers used are as follows: GAPDH (Forward 5’GAGAGACCCTCACTGCTG-3’, Reverse 5’- GATGGTACATGACAAGGTGC -3’), PHLPP1 (Forward 5’- ACTGGGATTTGGGGAGCTG -3’, Reverse 5’- CGTCTTGTCCATCGGTTCACT -3’) and PHLPP2 (5’- ATGGAGCAGACACTACCACTG -3’, Reverse 5’- GCAAAGGACGAGATGTAAGTCA -3’. Quantitative PCR experiments were performed using the 7500-Fast Real-time PCR system (Applied Biosystems) and relative mRNA concentrations were calculated by the 2-ΔΔCt method, where Ct is the mean threshold cycle value and GAPDH was used to normalize. Adenoviral Infection of CLL Cells- The PHLPP1 adenoviral construct was provided by Dr. Joan Heller Brown and prepared by Dr. Atsushi Miyanohara at the UCSD Viral Vector Core. Fresh CLL PBMCs were infected in 50 μl drops at 5x107 cells/mL at an MOI of 300 pfu/cell and incubated for 2 h at 37°C/5%CO2. Following adenoviral infection, CLL cells were resuspended at 1x107 cells/mL in RPMI + 10% heat inactivated serum and cultured for 72 h in plates containing a 3T3 fibroblast layer at ~70% confluence. CXCL12 Stimulation, Protein Lysates and Western Blots- Western blot lysates from purified CLL B cells were prepared using ice cold RIPA buffer as previously described (21). CLL cells infected with adenoviral-GFP or adenoviral-PHLPP1 for 72 h were cultured in serum-free RPMI at 1x107 cells/ml for 4 h at 37°C/5%CO2 and then stimulated with 30 nM CXCL12 over an hour time course. CXCL12 used for stimulations was expressed recombinantly in BL21 E. coli as previously described (22). Total protein concentrations were determined by a BCA protein assay (Thermo Scientific) and western blots were performed as previously described (21). PHLPP1 and PHLPP2 (PHLPPL) antibodies were obtained from Bethyl Laboratories, phospho-ERK1/2 and ERK1/2 antibodies were from Upstate, PKC antibodies were from Santa Cruz, and all other antibodies were acquired from Cell Signaling Technology. Densitometry analysis was performed using ImageJ software (NIH) and normalized to β-actin loading controls. Bisulfite DNA Conversion and Sequencing- Genomic DNA (500 ng) was bisulfite converted using the EZ DNA Methylation Kit (Zymo Research). PCR amplification of bisulfite-converted DNA was carried out using Hot Start Taq (Qiagen) in 1x reaction buffer, 250 μM dNTP mix, 1 μM of each primer, 2.5 mM MgCl2, and 5% DMSO. Primers used to probe the region of interest of PHLPP1 are: Forward 5’-GAGGGTTATTGATAGTT-3’ and Reverse 5’- CAAAACAAATAACTTCCTTACC-3’. Primers used to probe the PHLPP1 promoter and other CpG regions in exon 1 are included in Supplemental Figure 7. The PCR reactions were performed under the following conditions: 95°C for 15 min, then 40 cycles of 95°C for 1 min, 58°C for 1 min, and 72°C for 1 min, followed by 72°C for 7min. PCR products were gel purified (Qiagen gel extraction kit) and cloned into a TOPO/TA vector (Invitrogen). For each patient DNA sample, 510 colonies were sequenced and the fraction of methylated CpGs was calculated across the entire region. As a positive control for bisulfite conversion, in vitro methylation of DNA using SSSI (New England Biolabs) was performed. DNA sequencing was performed by the DNA Sequencing Shared Resource, UCSD Cancer Center, which is funded in part by NCI Cancer Center Support Grant # 2 P30 CA023100-23. Analysis of PHLPP1 mRNA Stability and Inhibition of DNA Methylation- To assess PHLPP1 mRNA stability, cells were treated with 5 μg/mL of Actinomycin D (Calbiochem) and RNA was harvested at 0, 2, and 4 h following treatment (levels stabilized after 4 h). Reverse transcription and quantitative PCR was carried out as described above and values were normalized to GAPDH levels. To examine the effects of DNA methylation on PHLPP1 mRNA expression, EHEB and Ramos cell lines were left untreated or treated with 5-aza-2’-deoxycytidine (5-aza DC) (Sigma) (0 to 25 μM) for 72 h. RNA isolation, cDNA synthesis, and quantitative PCR were performed as described above. DNA sequencing for mutations- The primers used to amplify the genomic regions of PHLPP1 were designed using Primer 3, to cover the exonic regions plus at least 50 bp of intronic sequences on both sides of intron-exon junctions (Supplemental Table 2). The PCR reactions were carried out using the Hotstart Kapa Fast Taq kit (Kapa Biosystems). DNA sequencing was completed by the UCSD cancer center shared DNA sequencing resource (see above) using primers listed in Supplemental Table 3. Flow Cytometry- Cells (~500,000) were stained for CXCR4 expression using a PE-conjugated antibody (BD Pharmingen) or corresponding PE-conjugated IgG isotype control (BD Pharmingen) in 100 μl of 0.5% BSA-PBS. CD19-APC, CD3-PE, and CD14-Fluorescein antibodies were obtained from R&D systems. Flow cytometry data was collected on a FACSCalibur cytometer (BD Biosciences) and analyzed using FlowJo software. SUPPLEMENTAL DATA Supplemental Table 1. DNA sequencing analysis of PHLPP1. Detailed information regarding the DNA changes of PHLPP1 including: the PCR reaction that covered the sequence (Rxn #), the NCBI reference number from the SNP database (NCBI ref #), the chromosome 18 genomic contig number from the GCRh37.p2 reference primary assembly (Contig #), and genotype frequency in our sample group (Frequency). Supplemental Table 2. List of sequencing reactions performed to cover the PHLPP1 gene including the PHlPP1β extension. The PCR additives 1M betaine (B) and 5% DMSO (D) were included for the indicated reactions and the primers used for the sequencing reactions are also shown. Supplemental Table 3. Sequence of primers used for amplification and sequencing of PHLPP1. Forward (F) and Reverse (R) PCR primers for sequencing the PHLPP1 gene. Abbreviations include the following: NF= Nested Forward, BF= Beta Forward, BR= Beta Reverse, and BSEQ1 and 2 are the primers for sequencing the PHLPP1β region. Supplemental Figure 1. PHLPP1 protein expression correlates with mRNA expression levels in B cell leukemia/lymphoma cell lines. Western blot of relative PHLPP1 protein expression in a Ramos Burkitt’s lymphoma line and two CLL cell lines, EHEB and WaC3CD5+ cells (top panel) and corresponding relative mRNA expression as assessed by quantitative RT-PCR (bottom panel). Supplemental Figure 2. PHLPP1 over-expression reduces basal and CXCL12-induced Akt phosphorylation (S473) in WaC3CD5+ cells. Western blot comparing phospho-Akt (S473) at 0, 3 and 15 min after 30 nM CXCL12 stimulation in adenoviral PHLPP1 or adenoviral GFP transduced WaC3CD5+ cells. β-actin served as a loading control and GFP and PHLPP1 panels demonstrate successful adenoviral transduction. Supplemental Figure 3. Relative amount of CpG methylation across regions of the bisulfite converted PHLPP1 gene and promoter. DNA sequence of bisulfite converted PHLPP1 gene and promoter. Boxed sequences indicate the primers used to probe these regions (forward and reverse) and the red highlight indicates the ATG start site. Highlighted regions represent: whitenot probed, yellow- <15% CpG methylation across the region, green- >30% CpG methylation across the region, blue- >20% CpG methylation across region and this is the region used in quantitative analysis. In vitro DNA methylation using Sss1 (NEB) performed as a positive control results in ~45-50% CpG methylation across these regions. Fold change in PHLPP2 mRNA PHLPP2 mRNA Levels 1.5 1.0 0.5 0.0 0 0.5 5 25 Concentration 5-Aza DC (M) Supplemental Figure 4. PHLPP2 transcript levels are not changed following treatment with 5-aza DC. EHEB cells were treated with varying concentrations of 5-Aza DC from 0.5-25 μM or DMSO control for 72 h and the levels of PHLPP2 mRNA were compared by quantitative RTPCR. Values were normalized to GAPDH and results indicate fold changes in PHLPP2 mRNA levels. % Viability (based on Trypan Blue stain) VPA treatment of CLL cells 100 80 60 40 ** p<0.001 20 0 DMSO control 10 mM VPA Supplemental Figure 5. Viability of CLL cells following treatment with VPA. Purified CLL cells from 2 patients were treated with 10 mM (on right) and 20 mM (not shown) VPA or DMSO control (on left) and cultured for 72 h. Cell viability was measured based on cell count and trypan blue staining (% viability= non blue cells/total number of cells). Statistical significance was calculated based on a student’s t-test (mean +/- SD). Relative mRNA levels Relative transcript stability 1.0 CLL PHLPP1 CLL PHLPP2 0.8 0.6 0.4 0.2 0.0 0 1 2 3 4 Time Actinomycin D (h) 5 Supplemental Figure 6. Relative transcript stability of PHLPP1 and PHLPP2 in CLL cells following treatment with Actinomycin D. Relative levels of PHLPP1 and PHLPP2 mRNA at 0 h, 2 h, and 4 h following 5 μg/mL Actinomycin D treatment were compared by quantitative RTPCR in CLL cells expressing low but detectable PHLPP1 mRNA. Data represents average from 3 different CLL patients. Experiments were performed in triplicate. Error represents the standard deviation of the mean. Supplemental Figure 7. Primers used to PCR amplify regions of bisulfite converted PHLPP1 gene and promoter. DNA sequence of bisulfite converted PHLPP1 gene and promoter (assuming CpG sites are methylated and retained) (left). Boxed sequences indicate the primers used to probe these regions (forward = odd number and reverse = even number primers) and the red highlight indicates the ATG start site. The primer sequences, listed in pairs of forward and reverse primers for different PCR amplifications, are shown on the right.